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Summary
It was the objective of this study to analyse the influence of con-
founders,such as ethnicity,severity of illness and method of test-
ing, in articles concerning the still moot relationship of throm-
bophilias to adverse pregnancy outcome (APO). Relevant case-
control studies were identified using Medline and EMBASE data-
bases between 1966 and 2006. Search terms were recurrent
fetal loss, intrauterine fetal death, preeclampsia, HELLP-syn-
drome, eclampsia, fetal growth restriction, abruptio placentae,
combined with maternal thrombophilias. Data was extracted
from the articles per subgroup ofAPO regardless of confounder.
These subgroups were tested if they fulfilled the heterogeneity
testing criterion (I
2
> 35%) to weigh the influence of the con-
founder.Confounders were selected and examined with Mantel-
Haenszel method. Increased thrombophilia prevalence was con-
firmed in most adverse pregnancy outcomes. Ethnicity, genetic
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testing only and severity of illness were confounders in the vari-
ous forms of APO. Stronger relationships between factor V
Leiden and severity of disease were found in 2
nd
and 3
rd
tri-
mester than 1
st
trimester recurrent fetal loss, in preeclampsia
with: blood pressure ≥160/110 mmHg than ≥140/90 mmHg;
proteinuria ≥5 grams per day than < 5 grams; onset before than
after 28 weeks, in fetal growth restriction <3
rd
percentile than
<5
th
, than <10
th
, and in earlier occurrence of abruptio placentae
than 3
rd
trimester. In conclusion, reports on the prevalence of
maternal thrombophilias and APO are influenced by various
confounders, which are not always appropriately analysed.The
differences we have identified reflect the differential impact of
these confounders. These data emphasise the importance of
more uniform research.
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Introduction
The influence of pregnancy on haemostasis and vice versa has
been of great interest in obstetric medicine. A clear relationship
between non-hereditary factors (antiphospholipid antibodies)
and adverse pregnancy outcome has been previously confirmed,
providing a paradigm for the hypothesis that an increased ten-
dency to hypercoagulability leads to pregnancy complications
(1–6).There is an ongoing proliferation of research attempting to
clarify the association between hereditary thrombophilic dis-
orders, including antithrombin deficiency, protein C deficiency,
protein S deficiency, activated protein C resistance, factor V
Leiden mutation, prothrombin gene G20210A mutation and the
common polymorphisms (C677T and A1298C) of the gene for
methylenetetrahydrofolate reductase (MTHFR), and adverse
pregnancy outcome (APO).
Despite numerous publications, however, concerning the
prevalence of such inherited thrombophilias in women with
APO, the relationship remains moot, while the heterogeneity
among study results is undeniable. In numerous reviews pub-
lished with the aim of elucidating the relationship, only a few
have mentioned the possible influence of confounders such as
ethnicity (7–12). This review will focus on the heterogeneity be-
tween published studies with the aim of identifying and compar-
ing confounders, so as to provide a clearer view on the relation-
ships of thrombophilias to APO.
Methods
To study possible causes of heterogeneity in studies on throm-
bophilia and APO, articles were selected pertaining to the vari-
ous thrombophilic disorders and using APO as an outcome
measurement.
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Figure 1: Relationships with FVL per
adverse pregnancy outcome regardless
of and regarding to confounders.
A) Recurrent fetal loss;
B) Preeclampsia;
C) Fetal growth restriction;
D) Abruptio placentae.
A)
B)
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Identification of relevant case-control studies
Case-control studies were identified by searching the Medline
and EMBASE databases between 1966 and November 2006 for
terms relating to recurrent fetal loss (RFL), intrauterine fetal
death (IUD), preeclampsia (PE), HELLP-syndrome, eclampsia,
fetal growth restriction (FGR), abruptio placentae (AP) and fetal
thrombophilia, combined with antithrombin deficiency, protein
C deficiency, protein S deficiency, activated protein C resistance
(APCR), factor V Leiden mutation (FVL), prothrombin gene
G20210A mutation (PGM), hyperhomocysteinemia (Hhcy),
methylenetetrahydrofolate reductase (MTHFR) C677T and
A1298C polymorphisms, antiphospholipid antibodies, anticar-
diolipin antibodies (ACA) and lupus anticoagulant (LAC).
Only case-control studies published in the English language
were accepted for meta-analysis. Their references were explored
for other publications. Data was extracted by four reviewers (J. I.
P. de Vries, J. J. Kalk, N. G. Janssen, W. J. Kist).
The set-up of the meta-analysis followed three steps. Firstly,
all articles were categorized and analyzed per subgroup of APO
(RFL, IUD, PE, FGR, AP) in relation to each thrombophilia re-
gardless of confounder. Secondly, these subgroups were tested to
see if they fulfilled the heterogeneity testing criterion (I
2
> 35%)
to weigh the influence of the various confounders (13). Finally,
articles were selected which established a clear definition of the
researched confounders so as to analyse the influence of the vari-
ous confounders on the relationship between thrombophilias and
APO, using RevMan software version 4.2.8 with the Mantel-
Haenszel method for combining trials. The Mantel-Haenszel
method is a statistical method for adjusting for confounding fac-
tors when analysing the relationship between a dichotomous out-
come and a dichotomous risk factor.
Definition of potential confounders
1. Ethnicity: Articles were selected where the ethnic composi-
tion of their control and study groups was defined.
2. Severity of the illness: Articles were selected where the fol-
lowing categories were distinguished: recurrent fetal loss
(RFL) during 1
st
trimester; RFL during 2
nd
and 3
rd
trimesters;
preeclampsia (PE), defined by a blood pressure of
≥140/90 mmHg; severe PE, defined by a blood pressure of
≥160/110 mmHg, with proteinuria <5 grams per 24 hours;
severe PE with proteinuria ≥5 grams per 24 hours; ges-
tational age at delivery in preeclamptic women of <28 weeks;
gestational age at delivery in preeclamptic women at any ges-
D)
C)
Figure 1: Continued.
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tation; fetal growth restriction (FGR) resulting in a birth
weight below the 10
th
, 5
th
and 3
rd
percentiles respectively;
FGR in combination with other APO; gestational age at birth
in women with FGR; gestational age at birth in women with
abruptio placentae (AP).
3. Method of testing: Articles were selected where one or more
genetic polymorphisms associated with thrombophilia, e.g.
FVL, (which can be ascertained at any time), had been tested
for – “genetic testing”, or where a functional test, e.g. APCR
or Protein S deficiency, (which may be affected by pregnan-
cy), had been performed – “functional testing”, or where both
genetic and functional tests had been performed.
Results of the meta-analyses
The search strategy revealed 98 case-control studies focused on
the various subgroups of APO. Of all thrombophilic anomalies
tested in these studies, only FVL, APCR, PGM, MTHFR and
Hhcy met the criteria for testing potential confounders.The find-
ings are presented below by subgroup of APO. Since FVL was
tested in all subgroups, it is presented in several tables by sub-
group of APO (Fig. 1A: recurrent fetal loss, B: preeclampsia, C:
fetal growth restriction and D: abruptio placentae).
Recurrent fetal loss
Ethnicity
Forty-one articles were found analysing the relationship between
RFL, intra-uterine death (IUD) and FVL (14–54). Out of these
41, 27 could be used in a meta-analysis of the ethnicity con-
founder.The 18 studies on non-Israeli Caucasian women (15, 16,
20, 24–26, 29, 31, 32, 34, 39, 41–44, 51–53) produced a weaker
relationship (odds ratio [OR] 1.83: 95% confidence interval [CI]
1.47–2.29), and nine studies conducted in Israel (17, 19, 21, 23,
33, 35, 40, 46, 50) showed a stronger relationship (OR 3.45: 95%
CI 2.47–4.82).
Severity of illness
Of the 41 articles mentioned, 23 could be used in a meta-analy-
sis of severity of illness, which showed that, regardless of this
particular confounder, there was a relationship with FVL (OR
2.03: 95% CI 1.61–2.56). The relationship was weaker in respect
of 1
st
trimester loss (17, 25, 28, 29, 36, 39, 41, 42, 45, 47, 53, 54),
when compared with loss in the 2
nd
and 3
rd
trimesters (15, 19, 25,
27, 30–33, 35–37, 39–41, 49).
Method of testing
Of the 49 articles on the relation between a thrombophilia and
APO, 27 used genotyping and functional testing, 13 used geno-
typing only and seven used functional testing only.
In the nine studies that conducted an APCR assay (17, 21,
23–25, 38, 46, 47, 53), the relationship of APCR with APO was
stronger than the relationship of FVL with APO in the 28 studies
that performed a FVL assay alone (15, 18, 19, 22, 26–37, 40–45,
48–52, 54).
Preeclampsia
The subgroup of articles addressing PE and MTHFR C677T
homozygous was the only subgroup that did not have an I
2
value
of 35% or higher (I
2
18%), but was analyzed because of the large
number of studies (19 out of 40).
Ethnicity
Twenty-four studies were identified studying the relationship be-
tween FVL and PE (35, 49, 55–76), of these 16 could be used in
the meta-analysis addressing the issue of ethnicity. Fourteen ar-
ticles that documented a Caucasian population (49, 55–57,
59–63, 65, 70, 72, 73, 76) showed a stronger relationship be-
tween FVL and PE than in the three studies on the association be-
tween FVL and PE in non-Caucasians (61, 69, 71) in which
neither patients nor controls were shown to carry the mutation.
Two of these studies used solely non-Caucasian populations (68,
70).
Nineteen articles were identified studying the relationship of
PE and MTHFR C677T homozygous (35, 55, 59, 60, 64–66, 70,
77–87) and confirmed a significant relationship (OR 1.54: 95%
CI 1.30–1.82). Of these 19 articles, 15 addressed the issue of eth-
nicity. Nine articles on Caucasian subjects (55, 59, 60, 65, 70, 80,
83, 84, 87) showed a stronger relationship of PE with MTHFR
C677T homozygous (OR 1.68: 95% CI 1.37–2.07) than three ar-
ticles on Asian subjects (78, 79, 86) where the relationship was
not significant (OR 1.15: 95% CI 0.76–1.74). Three articles
using African subjects (77, 81, 85) also did not demonstrate a
significant relationship (OR 1.53: 95% CI 0.34–6.94).
Severity of illness
Of the 24 studies addressing the relationship between PE and
FVL, half used a cut-off of ≥140/90 mmHg to define PE (55, 56,
59, 61, 62, 65, 67, 69, 70, 72, 74, 76), and the other half used a
cut-off of ≥160/110 mmHg to define severe PE (35, 49, 57, 58,
60, 65, 66, 68, 70, 71, 73, 75). Those studies with the lower cut-
off for blood pressure showed a weaker relationship between PE
and FVL than the studies that used more severe hypertension to
define the study population. Articles where proteinuria ≥ 5
grams per 24 hours was used as a criterion for severe PE (35, 49,
57, 65, 68, 70, 73) showed a stronger relationship of PE with
FVL than those articles that used proteinuria <5 grams per 24
hours as the definition (58, 60, 66, 75).
Of the 19 articles addressing the relationship between PE and
MTHFR C677T homozygous, the six studies that used ≥160/110
mmHg as a criterion for definition (35, 60, 65, 66, 70, 79)
showed a stronger relationship (OR 1.77: 95% CI 1.32–2.38)
than that in 13 articles that used a minimum blood pressure of
≥140/90 mmHg to define the diagnosis (55, 59, 65, 70, 77, 79,
81, 83–88) (OR 1.30: 95% CI 1.06–1.58). Two articles used both
definitions (78, 79), dividing their cases into mild and severe PE
groups.
One article (58) subcategorised severe PE by gestational age
at delivery before versus at or after 28 weeks gestation. To ascer-
tain the difference between making subgroups by gestational age
at delivery and not doing so, we compared the group of women
who delivered before 28 weeks with the total number of women.
In women with APCR (OR 14.49: 95% CI 1.77–118.60), with
FVL (OR 5.74: 95% CI 1.12–62.47), with Hhcy (OR 4.99: 95%
CI 1.32–18.9) and with ACA ≥10 (OR 3.84: 95% CI
1.40–10.50), although not in women with ACA ≥20, where
numbers were smaller, the ORs for severe PE were higher in the
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early onset group compared to the total number of women in both
study groups with APCR (OR 8.38: 95% CI 1.12–6.47), FVL
(OR 4.20: 95% CI 0.55–32.15), Hhcy (OR 2.94: 95% CI
0.88–9.86) and with ACA ≥10 (OR 2.68: 95% 1.11–6.47 CI).
Method of testing
Of the 38 articles documenting the relationship between a throm-
bophilia andAPO, seven used genotyping and functional testing,
25 articles used genotyping only and six articles used functional
testing only.
Within the 24 articles addressing the relationship of PE with
FVL, 21 studies that used genotyping alone (35, 49, 55–57,
59–61, 63–66, 68–76) showed a stronger association (OR 2.34:
95% CI 1.90–2.88) than the three studies in which both genotyp-
ing and APCR assay were used (OR 1.74: 95% CI 0.83–3.63)
(58, 62, 67). One article shows the importance of APCR testing
(55), since it reports a significant relationship between PE and
APCR, whereas there was no association of PE with FVL.
Since all 17 articles addressing the relationship of PE with
MTHFR C677T homozygous used genotyping alone, rather than
using the phenotype of Hhcy, a confounder analysis could not be
performed.
Fetal growth restriction
Ethnicity
Ten articles discussed the association of FGR with FVL regard-
less of confounder (49, 89–96, 100) and showed a significant re-
lationship (OR 2.05: 95% CI 1.41–2.99). Three of these address-
ed ethnicity (49, 95, 100) and showed a much stronger associ-
ation of FGR and FVL in the Caucasian group (OR 4.16: 95% CI
1.64–10.58). The same three articles also studied the association
of FGR and PGM in respect of ethnicity, showing comparable re-
Figure 2: Birth weight percentiles and
other adverse outcomes in women with
a history of FGR in respect of FVL (A)
and PGM (B).
A)
B)
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sults for the Caucasian group (OR 3.79: 95% CI 1.78–40.40)
compared with the data from all nine articles (49, 89–95, 100)
analyzed regardless of confounder (OR 2.07: 95% CI
1.33–3.23).
Severity of illness
All ten articles discussing the relationship between FGR and
FVL (49, 89–96, 100), and all nine articles considering FGR and
PGM (49, 89–95, 100) were used in a meta-analysis to compare
different incidences of the two genotypes in FGR below the 3
rd
,
the 5
th
and the 10
th
percentiles. For FVL, there was a stronger re-
lationship with the more profound degrees of FGR, whereas for
PGM the only significant relationship was seen for FGR <10
th
percentile. A second meta-analysis was performed, comparing
articles that used other adverse pregnancy outcomes as an exclu-
sion criterion with those that did not, showed a stronger relation-
ship of both FVL and PGM with FGR combined with other APO
(see Fig. 2).
In relation to FGR and gestational age at delivery, one study
identified a significant association between FVL and FGR in
women who delivered at a gestational age of 22–26 weeks (92).
In a second study (89), a significantly higher frequency of
thrombophilias was noted in women with FGR who delivered at
or after 37 weeks compared with women with FGR regardless of
gestational age. This study did not, however, document which
specific thrombophilias were linked to FGR at particular ges-
tational ages.
Method of testing
Of the 12 articles on thrombophilia and APO five articles used
genotyping and functional testing and seven used genotyping
only.
In respect of the association between FGR and FVL, the only
testing performed in all included articles was genotyping.
Abruptio placentae
Ethnicity
Six articles addressed the relationship of AP with FVL regard-
less of confounder (35, 49, 96–99) confirming a significant as-
sociation (OR 2.90: 95% CI 1.94–3.31). Only two of these ar-
ticles discussed ethnicity (49, 97), both articles dealing with
Caucasian populations. The relationship was very strong in the
Caucasian populations (OR 10.55: 95% CI 3.41–32.59), and
much less so, although still significant, when no account of eth-
nicity was taken.
Severity of illness
With regard to the confounder of gestational age at delivery, only
two out of six articles (98, 99) used 3
rd
trimester as a part of their
definition of AP in relation to FVL, giving a much less signifi-
cant relationship (OR 1.92: 95% CI 1.16–3.17) compared with
the other four articles (35, 49, 96, 97) that did not account for
gestational age at delivery (OR 7.55: 95% CI 3.42–16.64).
Method of testing
Of the 12 articles on thrombophilia and abruptio two used phe-
notype only, four used genotype only and six used both. As for
the relationship between AP and FVL, five articles used geno-
typing only revealing OR 2.62: 95% CI 1.73–3.96, and only one
article used both phenotyping and genotyping.
Discussion
This is the first study focusing on the effect of confounders in the
analysis of thrombophilia examined after APO. The meta-ana-
lyses reveal the confounding influence of ethnicity, severity of
disease and genotyping alone versus genotyping and phenotyp-
ing combined in all the examined varieties of APO.
When considering the prevalence of genetic thrombophilia
the knowledge of ethnicity will allow adjustment of results for
different populations: for example, the high prevalence of FVL
in Caucasians, and especially Israelis, needs to be considered in
relation to the incidence of recurrent fetal loss. The confounding
influence of ethnicity was not, however, limited to FVL alone but
could also be demonstrated in respect of MTHFR and PGM,
both examined in relation to preeclampsia.
Also striking was the varied influence of the severity of the dis-
ease in those forms of APO we could examine. Firstly, gestational
age at birth revealed a higher incidence of FVL in women with re-
current fetal loss in the 2
nd
and 3
rd
trimester than in those with re-
current 1
st
trimester loss. This is not surprising considering the ab-
sence of a functional intervillous space up to 9–10 week’s gesta-
tiona, i.e. it is highly unlikely that a thrombotic event could cause
embryonic loss prior to nine week’s gestation. In preeclampsia and
abruptio placentae the confounding influence seems to be the op-
posite, the earlier the gestational age at birth the higher the inci-
dence of FVL. In FGR both were found: one study described more
FVL at birth less than 26 weeks than at other gestational ages,
while another study found more FVL at delivery beyond 37 weeks
compared with delivery at other gestational ages. An explanation
could be that, although the aetiology of FGR is varied, a large part
is due to utero-placental insufficiency with the same origin (i.e.
thrombotic vasculopathy) as for preeclampsia.
Secondly, the severity in growth restriction showed the same
influence in both women with pregnancies complicated by FGR
or preeclampsia; the more severely growth restricted fetuses or
the earlier the onset of PE, the higher the incidence of FVL.
Thirdly, the elevation of the blood pressure had confounding
influence; the higher the blood pressure, the higher the incidence
of FVL.
Fourthly, the degree of proteinuria had similar confounding
influence; the more severe the proteinuria, the higher the inci-
dence of FVL
Fifthly, the studies on FGR that did not exclude other adverse
pregnancy outcomes had a higher incidence of thrombophilic
factors FVL and PGM than those that did. This leads to the sug-
gestion that multiple adverse pregnancy outcomes may be re-
lated to a higher incidence of FVL.
Genetic testing without functional testing limits the informa-
tion on the thrombophilic status of the subjects. This was found
for FVL and APCR in all forms of adverse pregnancy outcome.
From the work of Lachmeyer et al. (101) we know the limited
correlation between MTHFR and hyperhomocysteinemia. This
strengthens the need to elucidate the full thrombophilia status of
the patient, including a broad spectrum of functional clotting
tests (e.g. proteins S and C, antithrombin and APCR). Since
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some of these factors may be influenced by pregnancy (including
the postpartum period), the analyses need to be performed at a
suitable time thereafter.
A limitation of this study is the lack of uniformity among ar-
ticles, resulting in high heterogeneity. This was especially the
case in those articles relating to abruptio placentae, diminishing
the power of the confounder meta-analysis, since relatively few
articles could be used in each confounder analysis.
When confounders were analyzed, significant differences
became evident. To assess the true influence of a single con-
founder, every other variable in the comparison should ideally be
the same. In practice this rarely happens. The differences in ORs
between the overall meta-analyses and the relevant confounder-
based meta-analyses might therefore not be solely due to the in-
fluence of the investigated confounder. They do, however, give
an indication of the degree of impact of the various confounders
and provide an incentive for more uniform and well-defined re-
search. For example, heparin is increasingly used for prophylax-
is of pregnancy-associated morbidity in pregnant women with
thrombophilia (102). Two randomised controlled trials on the ef-
fect of heparin in women with unexplained first and second tri-
mester recurrent miscarriages did find a beneficial effect (103,
104). The trial authors, however, did not discuss whether or not
the effect was related to thrombophilia, nor did they consider if
the consequence is that even recurrent first trimester miscar-
riages have to be treated.The uncertainty about the role of throm-
bophilia is highlighted in that, although one trial (103) studied
women with antiphospholipid antibodies (without knowledge of
other thrombophilic factors), the other trial (104) found the ef-
fect to occur in women even in absence of antiphospholipid anti-
bodies or other thrombophilia factors. The uncertainty about the
consequence of treatment of recurrent first trimester miscar-
riages is increased, inasmuch as both trials lumped together their
data from first and second trimester miscarriages.
Conclusion
The prevalence of maternal thrombophilias and adverse preg-
nancy outcome has been demonstrated to be influenced by fac-
tors of ethnicity, severity of disease and methods of testing. Im-
portant influencing factors on the severity of disease are the ges-
tational age at birth, growth restriction, hypertension, proteinu-
ria and multiple adverse pregnancy outcomes. This study has
tried to address the knowledge of these aspects and thus to en-
hance the prospect of uniform research in the future.We strongly
suggest that the growing number of randomised controlled trials
on beneficial effect of low-molecular-weight heparin will care-
ful describe at least the three mentioned confounders: ethnicity,
severity of disease and the genotype and phenotype of the throm-
bophilia parameters, in relation to any adverse outcome of preg-
nancy to prevent premature introduction of treatment.
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